|
1
|
Low KC and Tergaonkar V: Telomerase:
Central regulator of all of the hallmarks of cancer. Trends Biochem
Sci. 38:426–434. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Maciejowski J and de Lange T: Telomeres in
cancer: Tumour suppression and genome instability. Nat Rev Mol Cell
Biol. 18:175–186. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pestana A, Vinagre J, Sobrinho-Simões M
and Soares P: TERT biology and function in cancer: Besyond
immortalisation. J Mol Endocrinol. 58:R129–R146. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Barthel FP, Wei W, Tang M,
Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang
Q, et al: Systematic analysis of telomere length and somatic
alterations in 31 cancer types. Nat Genet. 49:349–357.
2017.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Sreedevi A, Javed R and Dinesh A:
Epidemiology of cervical cancer with special focus on India. Int J
Womens Health. 7:405–414. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Schiffman M, Wentzensen N, Wacholder S,
Kinney W, Gage JC and Castle PE: Human papillomavirus testing in
the prevention of cervical cancer. J Natl Cancer Inst. 103:368–383.
2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cancer Genome Atlas Research Network;
Albert Einstein College of Medicine; Analytical Biological
Services; Barretos Cancer Hospital; Baylor College of Medicine;
Beckman Research Institute of City of Hope; Buck Institute for
Research on Aging; Canada's Michael Smith Genome Sciences Centre;
Harvard Medical School; Helen F. Graham Cancer Center &
Research Institute at Christiana Care Health Services, et al:
Integrated genomic and molecular characterization of cervical
cancer. Nature 543: 378.384, 2017.
|
|
8
|
Khurana E, Fu Y, Chakravarty D, Demichelis
F, Rubin MA and Gerstein M: Role of non-coding sequence variants in
cancer. Nat Rev Genet. 17:93–108. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Horn S, Figl A, Rachakonda PS, Fischer C,
Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al:
TERT promoter mutations in familial and sporadic melanoma. Science.
339:959–961. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liu X, Bishop J, Shan Y, Pai S, Liu D,
Murugan AK, Sun H, El-Naggar AK and Xing M: Highly prevalent TERT
promoter mutations in aggressive thyroid cancers. Endocr Relat
Cancer. 20:603–610. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026.
2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Vinothkumar V, Arunkumar G, Revathidevi S,
Arun K, Manikandan M, Rao AK, Rajkumar KS, Ajay C, Rajaraman R,
Ramani R, et al: TERT promoter hot spot mutations are frequent in
Indian cervical and oral squamous cell carcinomas. Tumour Biol.
37:7907–7913. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Park CK, Lee SH, Kim JY, Kim JE, Kim TM,
Lee ST, Choi SH, Park SH and Kim IH: Expression level of hTERT is
regulated by somatic mutation and common single nucleotide
polymorphism at promoter region in glioblastoma. Oncotarget.
5:3399–3407. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Spiegl-Kreinecker S, Lotsch D, Ghanim B,
Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G,
Pichler J and Berger W: Prognostic quality of activating TERT
promoter mutations in glioblastoma: Interaction with the rs2853669
polymorphism and patient age at diagnosis. Neuro Oncol.
17:1231–1240. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mosrati MA, Malmström A, Lysiak M,
Krysztofiak A, Hallbeck M, Milos P, Hallbeck AL, Bratthäll C,
Strandéus M, Stenmark-Askmalm M and Söderkvist P: TERT promoter
mutations and polymorphisms as prognostic factors in primary
glioblastoma. Oncotarget. 6:16663–16673. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ko E, Seo HW, Jung ES, Kim BH and Jung G:
The TERT promoter SNP rs2853669 decreases E2F1 transcription factor
binding and increases mortality and recurrence risks in liver
cancer. Oncotarget. 7:684–699. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ostör AG: Natural history of cervical
intraepithelial neoplasia: A critical review. Int J Gynecol Pathol.
12:186–192. 1993.PubMed/NCBI
|
|
18
|
Green MR: Molecular Cloning: A Laboratory
Manual. Green MR and Sambrook J (eds). Cold Spring Harbor
Laboratory Press, New York, NY, 2012.
|
|
19
|
Chen B, Cole JW and Grond-Ginsbach C:
Departure from Hardy Weinberg equilibrium and genotyping error.
Front Genet. 8(167)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA statement. PLoS Med.
6(e1000097)2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wallace BC, Dahabreh IJ, Trikalinos TA,
Lau J, Trow P and Schmid CH: Closing the gap between methodologists
and end-users: R as a computational back-end. J Stat Software.
49(15)2012.
|
|
22
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang J, Ju H, Gao JR, Jiao XL and Lu Y:
Polymorphisms in human telomerase reverse transcriptase (hTERT)
gene, gene-gene and gene-smoking interaction with susceptibility to
gastric cancer in Chinese Han population. Oncotarget.
8:20235–20243. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xing YL, Liu F, Li JF, Lin JC, Zhu GD, Li
M, Zhang CR and Niu YY: Case-control study on impact of the
telomerase reverse transcriptase gene polymorphism and additional
single nucleotide polymorphism (SNP)-SNP interaction on non-small
cell lung cancers risk in Chinese Han population. J Clin Lab Anal.
30:1071–1077. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bayram S, Ülger Y, Sümbül AT, Kaya BY,
Genç A, Rencüzoğullari E and Dadaş E: Polymorphisms in human
telomerase reverse transcriptase (hTERT) gene and susceptibility to
gastric cancer in a Turkish population: Hospital-based case-control
study. Gene. 585:84–92. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Oztas E, Kara H, Kara ZP, Aydogan MU, Uras
C and Ozhan G: Association between human telomerase reverse
transcriptase gene variations and risk of developing breast cancer.
Genet Test Mol Biomarkers. 20:459–464. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jannuzzi AT, Karaman E, Oztas E, Yanar HT
and Özhan G: Telomerase reverse transcriptase (TERT) gene
variations and susceptibility of colorectal cancer. Genet Test Mol
Biomarkers. 19:692–697. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yoo SS, Do SK, Choi JE, Lee SY, Lee J, Cha
SI, Kim CH and Park JY: TERT polymorphism rs2853669 influences on
lung cancer risk in the Korean population. J Korean Med Sci.
30:1423–1428. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shadrina AS, Boyarskikh UA, Oskina NA,
Sinkina TV, Lazarev AF, Petrova VD and Filipenko ML: TERT
polymorphisms rs2853669 and rs7726159 influence on prostate cancer
risk in Russian population. Tumour Biol. 36:841–847.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhong R, Liu L, Zou L, Zhu Y, Chen W, Zhu
B, Shen N, Rui R, Long L, Ke J, et al: Genetic variations in
TERT-CLPTM1L locus are associated with risk of lung cancer in
Chinese population. Mol Carcinog. 52((Suppl 1)): E118–E126.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Liu Z, Ma H, Wei S, Li G, Sturgis EM and
Wei Q: Telomere length and TERT functional polymorphisms are not
associated with risk of squamous cell carcinoma of the head and
neck. Cancer Epidemiol Biomarkers Prev. 20:2642–2645.
2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Shen J, Gammon MD, Wu HC, Terry MB, Wang
Q, Bradshaw PT, Teitelbaum SL, Neugut AI and Santella RM: Multiple
genetic variants in telomere pathway genes and breast cancer risk.
Cancer Epidemiol Biomarkers Prev. 19:219–228. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Park J, Chang H, Ahn S, Lee J, Kim D, Lee
K, Chon C, Moon Y and Han K: hTERT promoter gene polymorphism and
the risk of hepatocellular carcinoma (HCC) in patients with chronic
hepatitis. B. J Hepatol. 52:(Suppl 1): S345,. 2010.
|
|
34
|
Varadi V, Brendle A, Grzybowska E,
Johansson R, Enquist K, Butkiewicz D, Pamula-Pilat J, Pekala W,
Hemminki K, Lenner P and Försti A: A functional promoter
polymorphism in the TERT gene does not affect inherited
susceptibility to breast cancer. Cancer Genet Cytogenet. 190:71–74.
2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Savage SA, Chanock SJ, Lissowska J,
Brinton LA, Richesson D, Peplonska B, Bardin-Mikolajczak A,
Zatonski W, Szeszenia-Dabrowska N and Garcia-Closas M: Genetic
variation in five genes important in telomere biology and risk for
breast cancer. Br J Cancer. 97:832–836. 2007.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jiang Y, Chen C, Chen SM, Wang YQ, Xu Y,
Wang Y, Chen Z, Xiao BK and Tao ZZ: Telomerase reverse
transcriptase promotes the proliferation of human laryngeal
carcinoma cells through activation of the activator protein 1.
Oncol Lett. 6:75–80. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shay JW: Role of telomeres and telomerase
in aging and cancer. Cancer Discov. 6:584–593. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Liu R and Xing M: TERT promoter mutations
in thyroid cancer. Endocr Relat Cancer. 23:R143–R155.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shimoi T, Yoshida M, Kitamura Y, Yoshino
T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K,
Shimizu C, et al: TERT promoter hotspot mutations in breast cancer.
Breast Cancer. 25:292–296. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Thiem S, Herold T, Krafft U, Bremmer F,
Tolkach Y, Szász AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T
and Reis H: Telomerase reverse transcriptase (TERT) promoter
mutations are rare in urachal cancer. Pathol Int. 67:597–601.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Liu X, Dakic A, Chen R, Disbrow GL, Zhang
Y, Dai Y and Schlegel R: Cell-restricted immortalization by human
papillomavirus correlates with telomerase activation and engagement
of the hTERT promoter by Myc. J Virol. 82:11568–11576.
2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chen Y, Williams V, Filippova M, Filippov
V and Duerksen-Hughes P: Viral carcinogenesis: Factors inducing DNA
damage and virus integration. Cancers (Basel). 6:2155–2186.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Hsu CP, Hsu NY, Lee LW and Ko JL: Ets2
binding site single nucleotide polymorphism at the hTERT gene
promoter-effect on telomerase expression and telomere length
maintenance in non-small cell lung cancer. Eur J Cancer.
42:1466–1474. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bojesen SE, Pooley KA, Johnatty SE,
Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen
HC, Smart CE, et al: Multiple independent variants at the TERT
locus are associated with telomere length and risks of breast and
ovarian cancer. Nat Genet. 45:371–384, 384e1-2,. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Horikawa I, Cable PL, Afshari C and
Barrett JC: Cloning and characterization of the promoter region of
human telomerase reverse transcriptase gene. Cancer Res.
59:826–830. 1999.PubMed/NCBI
|
|
46
|
Helbig S, Wockner L, Bouendeu A,
Hille-Betz U, McCue K, French JD, Edwards SL, Pickett HA, Reddel
RR, Chenevix-Trench G, et al: Functional dissection of breast
cancer risk-associated TERT promoter variants. Oncotarget.
8:67203–67217. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Rachakonda PS, Hosen I, de Verdier PJ,
Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf
D, Hemminki K and Kumar R: TERT promoter mutations in bladder
cancer affect patient survival and disease recurrence through
modification by a common polymorphism. Proc Natl Acad Sci USA.
110:17426–17431. 2013.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Nagore E, Heidenreich B, Requena C,
García-Casado Z, Martorell-Calatayud A, Pont-Sanjuan V,
Jimenez-Sanchez AI and Kumar R: TERT promoter mutations associate
with fast-growing melanoma. Pigment Cell Melanoma Res. 29:236–238.
2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Bell RJA, Rube HT, Xavier-Magalhães A,
Costa BM, Mancini A, Song JS and Costello JF: Understanding TERT
promoter mutations: A common path to immortality. Mol Cancer Res.
14:315–323. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
McMurray HR and McCance DJ: Human
papillomavirus type 16 E6 activates TERT gene transcription through
induction of c-Myc and release of USF-mediated repression. J Virol.
77:9852–9861. 2003.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Liu X, Dakic A, Zhang Y, Dai Y, Chen R and
Schlegel R: HPV E6 protein interacts physically and functionally
with the cellular telomerase complex. Proc Natl Acad Sci USA.
106:18780–18785. 2009.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Shen N, Lu Y, Wang X, Peng J, Zhu Y and
Cheng L: Association between rs2853669 in TERT gene and the risk
and prognosis of human cancer: A systematic review and
meta-analysis. Oncotarget. 8:50864–50872. 2017.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Soerensen M, Thinggaard M, Nygaard M, Dato
S, Tan Q, Hjelmborg J, Andersen-Ranberg K, Stevnsner T, Bohr VA,
Kimura M, et al: Genetic variation in TERT and TERC and human
leukocyte telomere length and longevity: A cross-sectional and
longitudinal analysis. Aging Cell. 11:223–227. 2012.PubMed/NCBI View Article : Google Scholar
|
